Inhibition of the cardiac Na⁺ channel Nav1.5 by carbon monoxide

Jacobo Elies1, Mark L Dallas1, John P Boyle1

  • 1From the Division of Cardiovascular and Diabetes Research, Leeds Institute of Genetics, Health and Therapeutics, Faculty of Medicine and Health and.

Insights

Sublethal carbon monoxide (CO) exposure inhibits cardiac sodium channels (Nav1.5), potentially causing arrhythmias. This effect requires nitric oxide (NO) formation and depends on the channel

Area of Science:

  • Cardiovascular Physiology
  • Molecular Cardiology
  • Toxicology

Background:

  • Sublethal carbon monoxide (CO) exposure is linked to myocardial arrhythmias.
  • Previous research suggests CO modulates cardiac sodium channels, affecting peak and late currents.

Purpose of the Study:

  • To investigate the mechanism by which CO inhibits human cardiac sodium channels (Nav1.5).
  • To determine the role of nitric oxide (NO) and channel redox state in CO-mediated inhibition.

Main Methods:

  • Utilized a recombinant expression system to study human Nav1.5 channels.
  • Applied electrophysiological techniques to measure sodium current.
  • Investigated the effects of CO in the presence of NO inhibitors, NO donors, and reducing agents (DTT, l-cysteine).

Main Results:

  • CO inhibited peak Nav1.5 current amplitude without activating the late current.
  • Inhibition involved a hyperpolarizing shift in steady-state inactivation and was unaffected by rATX-II.
  • CO-induced inhibition was suppressed by NO formation inhibitors and reducing agents, indicating a redox-dependent mechanism involving NO.

Conclusions:

  • CO inhibits peak Nav1.5 current via a mechanism distinct from late current induction.
  • This inhibition is dependent on nitric oxide (NO) formation and the channel's redox state.
  • Findings suggest a novel mechanism for CO-induced arrhythmias, potentially linked to Brugada syndrome.

Related Concept Videos

Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
2.7K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.2K
G-Protein Gated Ion Channels01:21

G-Protein Gated Ion Channels

GPCRs are primarily responsible for our sense of smell, taste, and vision.  The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory...
5.5K
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
2.4K
Depolarizing Blockers: Mechanism of Action01:28

Depolarizing Blockers: Mechanism of Action

Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
3.4K